LEESBURG, Va., Nov. 12, 2014 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO) (the "Company" or "K2M"), a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies, techniques and minimally invasive procedures, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the CAPRI™ Corpectomy Cage System, an expandable vertebral body replacement device that provides structural stability following a corpectomy or vertebrectomy. K2M will offer a preview of CAPRI during the North American Spine Society (NASS) 2014 Annual Meeting in San Francisco at Booth #805.
"We are pleased to receive 510(k) clearance for the CAPRI Corpectomy Cage System, K2M's innovative and unique solution for stabilization of the spine that allows for intraoperative endplate manipulation," stated Eric Major, K2M's President and CEO. "As the Company continues to expand its presence in the complex spine market, this important milestone reinforces K2M's mission of developing differentiated technologies to improve the lives of patients."
The CAPRI Corpectomy Cage System is intended for use in the thoracolumbar spine (T1 to L5) to replace collapsed, damaged or unstable vertebral bodies due to tumor or trauma (i.e., fracture). The CAPRI Corpectomy Cage System is designed to provide anterior spinal column support even in the absence of fusion for a prolonged period.
CAPRI cages, manufactured from titanium and cobalt chrome, are offered in a variety of interchangeable footprint options, allowing for in-situ height expansion and endplate angulation to match the patient's anatomy. Additionally, the device may be implanted through an anterior, lateral or posterior approach.
According to Michael Finn, MD, a neurosurgeon and assistant professor in the department of neurosurgery at the University of Colorado: "The continuous variability of endplate angulation and height expansion is designed to reduce the time it takes to place the corpectomy cages."
For more information on K2M's complete product portfolio, visit www.K2M.com.
K2M Group Holdings, Inc. is a global medical device company focused on designing, developing and commercializing innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most difficult and challenging spinal pathologies. K2M has leveraged these core competencies to bring to market an increasing number of products for patients suffering from degenerative spinal conditions. These technologies and techniques, in combination with a robust product pipeline, enable the Company to favorably compete in the global spinal surgery market. Additional information is available online at www.K2M.com.
Certain statements made in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are based on management's expectations, estimates, projections, and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Additional information regarding these factors is contained in the Company's Registration Statement on Form S-1 filed with the SEC.
CONTACT: Media Contact Zeno Group on behalf K2M Group Holdings, Inc. Marcie Kohenak, 202-965-7811 Marcie.Kohenak@ZenoGroup.com
Source:K2M Group Holdings, Inc.